Emerging Novel Therapies for Ankylospondylitis

Abstract

Description

Ankylosing Spondylitis (AS) (also known as axial spondyloarthritisis) an uncommon form of arthritis characterized by prolonged inflammation of the spine's joints, causes fibrosis of the sacroiliac joints, which are positioned between the pelvis and the back of the spine. The inflammation, known as sacroiliitis, is one of the early symptoms of AS. Inflammation frequently spreads to the joints between the vertebrae, which make up the spinal column. Other joints, such as the shoulders or hips, may occasionally be impacted. Back discomfort, as well as eye and gastrointestinal problems, are attainable. Joint mobility in affected areas deteriorates over time.

7 to 490 persons worldwide suffer from ankylosing spondylitis for every 100,000 people [1]. There is no recognized cause of AS. Genes appear to be important. The HLA-B27 gene is largely associated with AS, however not everyone who carries this gene experiences AS does [2]. 80% of those with Ankylosing Spondylitis (AS) begin to experience symptoms before the age of 30, but only 5% are experiencing symptoms by the time they are 45. The illness affects 0.1% to 0.8% of the population, and it typically first appears in young adults. Both sexes have the same consequences, but women are more likely than males to experience fusion than inflammation. Although the precise cause of ankylosing spondylitis is unknown, it is believed that a combination of hereditary and environmental factors are to blame [2].

Here are some other types of spondyloarthritis:

• The main symptoms of non-radiographic axial spondyloarthritis, which is diagnosed based on symptoms, blood tests, and other imaging tests rather than an X-ray, include pain and stiffness around the spine. This disorder is comparable to ankylosing spondylitis.

• Psoriatic spondyloarthritis, a kind of psoriatic arthritis, can develop concurrently with psoriasis, a skin ailment. Psoriasis patients may develop red, scaly patches of skin.

When children and teenagers experience inflammation in enthesis, the places where tendons and ligaments join to bones, it is referred to as enteritis-related juvenile idiopathic arthritis.

Back discomfort and stiffness in the lower back and hips, particularly in the morning and after periods of inactivity, are possible early signs of ankylosing spondylitis. Fatigue and neck ache are also frequent. Symptoms may get better or worse over time, or the sacroiliac joints may get injured. Over time, it could affect the spine entirely or in part. The lower spine may start to lose flexibility, which will make hunch forward. Persistent or recurrent uveitis (iritis) of the eyes. In addition to painful and swollen joints in shoulders, knees and ankles, one may also have damaged joints in the ribs and breastbone that prevent from expanding the chest entirely. A number of tests are used to diagnose ankylosing spondylitis, including CBC, ESR, HLA-B27 antigen, Rheumatoid factor, and X-rays and MRI of the spine and pelvis [3].

Ankylosing spondylitis does not currently have a known cure, although there are treatments that can aid with symptom relief. Treatment can also aid in delaying or halting the process of the spine fusing together and becoming stiff. Aspirin, ibuprofen (Advil, Motrin), and naproxen (Aleve, Naprosyn) are examples of Non-Steroidal Anti-Inflammatory Medicines (NSAIDs) that are used to reduce inflammation. Other NSAIDs include Sulfasalazine and corticosteroid treatment (prednisone) [4].

Emerging medicines and studies on Ankylosing Spondylitis (AS) includes

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), were once the only AS treatments that could treat symptoms like pain. In order to prevent joint injury, newer drugs actually slow the disease [5].

Tumor Necrosis Factor (TNF) inhibitors: Newer biologic medications to be developed for AS were TNF inhibitors. It functions by preventing the body from producing inflammatory mediators like cytokines. The Food and Drug Administration (FDA) has authorized the use of five TNF inhibitors for AS; Adalimumab (Humira), certolizumab (Cimzia), etanercept (Enbrel), infliximab (Simponi), and golimumab (Remicade) are some examples of anti-TNF medications.

Trials are also being conducted with anti-interleukin-6 inhibitors such tocilizumab, which is now licensed for the treatment of rheumatoid arthritis, and rituximab, a monoclonal antibody targeting CD20 [6].

Secukinumab and ixekizumab are interleukin-17A inhibitors that can be used to treat active ankylosing spondylitis in patients who did not respond well to TNF blockers.

Tofacitinib a Janus kinase inhibitor, is licensed for the treatment of active ankylosing spondylitis in adult patients who have previously received insufficient benefit from DMARD (disease-modifying anti-rheumatic medication) therapy.

References

1. Braun J, et al. Prevalence of spondylarthropathies in HLA‐B27 positive and negative blood donors. Arthritis Rheum. 1998;41:58-67.

   [Crossref] [Google scholar] [Pubmed]

2. Sieper J, et al. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006;20:401-417.

   [Crossref] [Google scholar] [Pubmed]

3. Heijde DV, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063-3070.

   [Crossref] [Google scholar] [Pubmed]

4. Schlosstein L, et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973;288:704-706.

   [Crossref] [Google scholar] [Pubmed]

5. Benjamin M, et al. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol. 2009; 649:57-70.

   [Crossref] [Google scholar] [Pubmed]

6. Baeten D, et al. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum. 2004;50:1611-1623.

   [Crossref] [Google scholar] [Pubmed]